Inj. prevnar 20?

Inj. Prevnar® 20 (also known as Prevnar 20 or Prevnar 20 vaccine)
— a pneumococcal conjugate vaccine that protects against 20 serotypes of Streptococcus pneumoniae (the bacteria that cause invasive pneumococcal disease such as pneumonia, meningitis, and sepsis).

---

1. What it is & how it works

Feature	Detail
Active ingredients	20 purified polysaccharide conjugates (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 23F, 24F, 25F, 33F) linked to a carrier protein (CRM197).
Mechanism	Conjugation turns a polysaccharide (normally T‑cell‑independent) into a T‑cell‑dependent antigen, inducing a robust, long‑lasting antibody response even in infants and the elderly.
Immunogenicity	Provides high serotype‑specific IgG titers that protect against invasive disease for at least 5 years; additional data suggest lasting protection up to 10 years in adults.

---

2. Indications

• Primary prevention

  • Children ≥ 6 weeks to 18 months – part of the routine infant schedule.
  • Children > 18 months to 5 years – catch‑up vaccination.
  • Adults ≥ 65 years – as a one‑time dose (not part of routine infant schedule).
  • Adults with certain medical conditions (e.g., immunocompromised, asplenia, cochlear implants, cochlear implant, HIV, chronic heart, liver, or lung disease) – as part of their preventive regimen.

• Secondary prevention

  • Adults who have received the 13‑valent conjugate vaccine (Prevnar 13) and need broader coverage against additional serotypes (e.g., serotype 22F, 33F).

---

3. Dosage & Schedule

Patient group	Recommended dose	Schedule
Infants 6–11 mo	0.5 mL SC or IM	2 weeks apart: 2, 4, 6, and 12 mo (four‑dose series)
Infants 12–23 mo	0.5 mL	2 weeks apart: 2, 4, 6, 12 mo (four‑dose series)
Children 24–59 mo (catch‑up)	0.5 mL	2 weeks apart: 2, 4, and 12 mo (three‑dose series)
Adults 65 + or at risk	0.5 mL	Single dose (no repeat dose recommended)
Adults who received Prevnar 13	0.5 mL	One dose (no repeat)

All doses are given intramuscularly (IM) or subcutaneously (SC) in the deltoid (or an appropriate site).

---

4. Contraindications

Contraindication	Reason
Known hypersensitivity to any vaccine component (e.g., polysaccharide, carrier protein, thimerosal, aluminum, latex)	Risk of severe allergic reaction
Severe acute illness with fever	Vaccine should be postponed until recovery
History of severe anaphylactic reaction to a previous dose of Prevnar 20 or any pneumococcal vaccine	Avoid risk of repeat severe reaction

---

5. Precautions

1. Allergy – Patients with a history of allergy to vaccine components should be monitored; pre‑medication is not routinely recommended.
2. Pregnancy / Lactation – Generally safe; no data suggest teratogenicity, but discuss with physician.
3. Immunocompromised – Vaccine is recommended; no live vaccine component, so safe.
4. Co‑administration – Can be given with other routine vaccines (e.g., influenza, DTaP/IPV/Hib).

---

6. Common Side Effects

Symptom	Typical Frequency
Pain, redness, swelling at injection site	10–30 % (usually mild)
Low‑grade fever (≤ 38 °C)	5–15 %
Irritability, crying (infants)	3–10 %
Fatigue, headache	< 5 %
Rare: anaphylaxis	< 1 case per 100,000 doses

---

7. Serious Adverse Events (rare)

• Anaphylaxis – immediate emergency treatment required.
• Seizure – very rare; consider if seizure disorder is present.
• Serious allergic reactions – monitor for signs of anaphylaxis after injection (difficulty breathing, swelling, hypotension).

---

8. Storage & Handling

• Temperature – 2 °C to 8 °C (refrigerated).
• Shelf‑life – 2 years from manufacturing date (after reconstitution).
• Reconstitution – Mix 0.5 mL of vaccine with 0.5 mL of sterile 0.9 % NaCl before use.
• Administration – Use a fresh syringe for each dose; do not reuse vials or syringes.

---

9. Drug Interactions

• No pharmacologic interactions – vaccine components do not interact with oral or injectable drugs.
• Immunosuppressants – may reduce antibody response; timing with immunosuppressive therapy should be coordinated with a clinician.

---

10. Cost & Insurance

• Price range (US): $50–$70 per dose (varies by pharmacy, insurance, or Medicaid coverage).
• Insurance – Most private insurers and Medicare cover Prevnar 20 for indicated age groups and high‑risk patients. Check with your insurer for pre‑authorization requirements.

---

11. FAQ

Question	Answer
Is Prevnar 20 a live vaccine?	No, it is a conjugate (non‑live) vaccine.
Can I get both Prevnar 13 and 20?	Yes – many adults receive a single dose of Prevnar 20 after completing the 13‑valent series for broader protection.
Do I need a booster after 5 years?	Generally not; antibody levels remain protective for at least 5 years. However, adults at high risk may be re‑vaccinated per local guidelines.
What if I have a fever before vaccination?	Postpone until fever resolves (≥ 24 h) to avoid confusion of vaccine reaction versus illness.

---

Bottom line

• Prevnar 20 is a safe, effective vaccine that protects against 20 pneumococcal serotypes.
• It is indicated for routine use in infants and certain adults, especially those at higher risk of invasive disease.
• Standard dosing is 0.5 mL IM/SC; side effects are usually mild and transient.
• Contraindications are rare, primarily hypersensitivity to vaccine components.

If you have specific health concerns, allergies, or are on immunosuppressive therapy, consult your healthcare provider for personalized recommendations.